← All reports

The European Federation of Pharmaceutical Industries and Associations (EFPIA) argues that Europe is becoming less attractive for pharmaceutical innovation due to declining R&D investment.

HealthcarePharmaceutical IndustryPoliticsEconomicsMay 26, 2026score 0.172 posts · 0 replies across 1 instances
The thread discusses the European Federation of Pharmaceutical Industries and Associations (EFPIA) chief's call for Europe to rethink how it values medicines, highlighting declining R&D investment and its impact on pharmaceutical innovation. This is significant as it addresses the future of healthcare innovation in Europe.

Claims

The European Federation of Pharmaceutical Industries and Associations (EFPIA) argues that Europe is becoming less attractive for pharmaceutical innovation due to declining R&D investment.
Parent: Pharmaceutical IndustryEntity: European Federation of Pharmaceutical Industries and Associations (EFPIA)Impact: negativeDate: May 26, 2026Target: Europe's attractiveness for pharmaceutical innovation

Source posts

@[email protected]
Europe must rethink how it values medicines, says EFPIA chief [Advocacy Lab] https://www.euractiv.com/interview/europe-must-rethink-how-it-values-medicines-says-efpia-chief/?utm_source=eac&utm_medium=mastodon&utm_campaign=%40euractiv%40masto.ai
0 boosts · 0 favs · 0 replies · May 26, 2026
@[email protected]
Europe must rethink how it values medicines, says EFPIA chief [Advocacy Lab]: Europe is becoming less attractive for pharmaceutical innovation after two decades of declining R&D investment, says pharma industry leader https://www.euractiv.com/interview/europe-must-rethink-how-it-values-medicines-says-efpia-chief/?utm_source=eac&utm_medium=mastodon&utm_campaign=%40euractiv_economy%40eupolicy.social
0 boosts · 0 favs · 0 replies · May 26, 2026